Nektar Therapeutics (NKTR) Gets a Buy from B.Riley Financial

Jan 8, 2025 · Nektar Therapeutics (NKTR – Research Report) received a Buy rating and a $4.00 price target from B.Riley Financial analyst Mayank Mamtani yesterday. The company’s shares …

$4.00
OFF

Nektar Therapeutics (NKTR) Gets A Buy From B.Riley Financial

2 weeks from now

Jan 8, 2025 · Nektar Therapeutics (NKTR – Research Report) received a Buy rating and a $4.00 price target from B.Riley Financial analyst Mayank Mamtani yesterday. The company’s shares …

businessinsider.com

$4
OFF

Nektar Initiated With A Buy At B. Riley - Markets Insider

2 weeks from now

Jan 8, 2025 · B. Riley last night initiated coverage of Nektar (NKTR) with a Buy rating and $4 price target The firm views Nektar’s most advanced T regulatory cell targeting candidate, …

businessinsider.com

$1.19
OFF

Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated At B. Riley

2 weeks from now

Jan 8, 2025 · View Our Latest Stock Report on NKTR Nektar Therapeutics Price Performance. Shares of NASDAQ:NKTR opened at $1.19 on Wednesday. Nektar Therapeutics has a one …

marketbeat.com

$4.08
OFF

Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded By

2 weeks from now

Jan 9, 2025 · According to MarketBeat, Nektar Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $4.08. Read Our Latest Report on NKTR …

marketbeat.com

$4
OFF

Nektar Initiated With A Buy At B. Riley - Markets Insider

2 weeks from now

Jan 8, 2025 · B. Riley initiated coverage of Nektar (NKTR) with a Buy rating and $4 price target Stay Ahead of the Market:Discover outperforming stocks and in...

businessinsider.com

$4.00
OFF

Nektar Stock Positioned For Growth As B. Riley Forecasts REZPEG As …

2 weeks from now

Jan 8, 2025 · On Wednesday, B.Riley initiated coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and a price target of $4.00. With the stock currently trading …

investing.com

$4
OFF

Nektar Initiated With A Buy At B. Riley - Nasdaq

2 weeks from now

Jan 8, 2025 · B. Riley initiated coverage of Nektar (NKTR) with a Buy rating and $4 price target Stay Ahead of the Market:Discover outperforming stocks and invest smarter with Top Smart …

nasdaq.com

$4.00
OFF

Nektar Stock Positioned For Growth As B. Riley Forecasts REZPEG As …

2 weeks from now

Jan 8, 2025 · On Wednesday, B.Riley initiated coverage on shares of Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating and a price target of $4.00.With the stock currently trading …

investing.com

50%
OFF

Nektar Therapeutics Buy B. Riley - Sharewise

2 weeks from now

6 days ago · Nektar Therapeutics buy B. Riley. Nektar Therapeutics. Start price €1.09. 08.01.25 / 50%. Target price €3.88. 08.01.26. Performance (%) 12.29% ... Some of its most advanced …

sharewise.com

11%
OFF

Nektar Rises 11% As BTIG Initiates Buy Rating On Autoimmune …

2 weeks from now

Sep 30, 2024 · Pgiam. BTIG has initiated Nektar Therapeutics (NASDAQ:NKTR) with a buy rating, citing the potential of rezpegaldesleukin, a potential first-in-class regulatory T cell …

seekingalpha.com

50%
OFF

Nektar Therapeutics Buy B. Riley - Sharewise

2 weeks from now

6 days ago · Nektar Therapeutics buy B. Riley. Nektar Therapeutics. Start price €1.11. 09.01.25 / 50%. Target price -09.01.26. Performance (%) -10.36%. ... Some of its most advanced …

sharewise.com

$6.50
OFF

Nektar Therapeutics: Promising Drug Pipeline And Strategic …

2 weeks from now

3 days ago · Analyst Arthur He CFA of H.C. Wainwright maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), retaining the price target of $6.50. Discover …

businessinsider.com

$4
OFF

B. Riley Securities Initiates Coverage On Nektar Therapeutics With …

2 weeks from now

Jan 8, 2025 · B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $4.

sahmcapital.com

$0.71
OFF

Nektar Therapeutics (NKTR) Stock Price, News & Analysis

2 weeks from now

6 days ago · Earnings for Nektar Therapeutics are expected to decrease in the coming year, from ($0.71) to ($0.81) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of Nektar …

marketbeat.com

$1
OFF

Bristol-Myers Squibb Makes History With Major Multibillion-dollar ...

2 weeks from now

Feb 14, 2018 · Bristol-Myers Squibb is paying Nektar Therapeutics $1 billion to develop NKTR-214 in combination with Opdivo and Yervoy. All told, Bristol-Myers is committing $3.6 billion to …

fiercebiotech.com

$7.00
OFF

Nektar Therapeutics (NKTR) Gets A Buy From Piper Sandler

2 weeks from now

6 days ago · Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of $7.00. The company’s …

businessinsider.com

FAQs about Nektar Therapeutics (NKTR) Gets a Buy from B.Riley Financial Coupon?

Should you buy Nektar Therapeutics (NKTR)?

Nektar Therapeutics (NKTR – Research Report) received a Buy rating and a $4.00 price target from B.Riley Financial analyst Mayank Mamtani yesterday. The company’s shares closed yesterday at $1.19. Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Harrow Health, and Arrowhead Pharmaceuticals. ...

What was Nektar Therapeutics' stock price on January 1st 2024?

Nektar Therapeutics' stock was trading at $0.5650 on January 1st, 2024. Since then, NKTR shares have increased by 141.0% and is now trading at $1.3615. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, August, 8th. ...

Is Nektar Therapeutics a good investment?

NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $1.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low. ...

How did Nektar Therapeutics perform compared to last year?

Based on Nektar Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $24.12 million and a GAAP net loss of $37.06 million. In comparison, last year the company earned a revenue of $24.14 million and had a GAAP net loss of $45.84 million ...

Who is Nektar Therapeutics?

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. ...

Should you buy Mamtani (Nektar)?

According to TipRanks, Mamtani has an average return of -12.2% and a 28.80% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nektar Therapeutics with a $5.83 average price target. ...